K. Heard

Phase 2 Open‐Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle‐Cell and Indolent Lymphomas

D. Mahadevan, J. Schatz, J. Guillén-Rodríguez, 2018, Clinical lymphoma, myeloma & leukemia.

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

J. Schatz, M. Schmelz, J. Guillén-Rodríguez, 2017, Oncology.

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

D. Mahadevan, J. Schatz, J. Guillén-Rodríguez, 2018, Oncology.

First-row transitional-metal oxalate resists for EUV

Yasin Ekinci, Michaela Vockenhuber, Brian Cardineau, 2018, Journal of Micro/Nanolithography, MEMS, and MOEMS.